R1	AND Arg1:T2 Arg2:T3	
R2	Has_value Arg1:T4 Arg2:T5	
R3	AND Arg1:T1 Arg2:T4	
R4	Has_qualifier Arg1:T1 Arg2:T2	
R5	Has_temporal Arg1:T7 Arg2:T8	
R6	AND Arg1:T11 Arg2:T9	
R7	Has_qualifier Arg1:T7 Arg2:T11	
R8	Has_value Arg1:T14 Arg2:T13	
R9	AND Arg1:T12 Arg2:T14	
R10	Has_value Arg1:T18 Arg2:T19	
T1	Condition 41 51	malignancy
T2	Qualifier 52 82	suitable for radiation therapy
T3	Procedure 65 82	radiation therapy
T4	Procedure 19 29	histologic
T5	Value 30 35	proof
T6	Subjective_judgement 52 82	suitable for radiation therapy
T7	Procedure 119 150	external beam radiation therapy
T8	Temporal 113 118	prior
T9	Procedure 178 195	HDR brachytherapy
T10	Not_a_criteria 207 373	evaluation of doses previously delivered to spinal cord/cauda equine, pelvis, and other critical structures (bowel, kidneys, rectum) will be taken into consideration.
T11	Qualifier 151 205	to the region proposed for HDR brachytherapy treatment
T12	Procedure 378 396	repeat irradiation
T13	Value 403 438	exceed any normal tissue constraint
T14	Measurement 446 506	MSKCC Radiation Oncology Department dose constraint criteria
T15	Context_Error 551 964	If the total prior radiation dose to the cord or pelvis exceeds 100 Gy BED equivalent, the patient will be potentially eligible, where a total of 100 BED Gy equivalent is determined by the biological equivalent dose (BED) calculation; BED = nd(1 + d/α/β), where n = number of fractions and d = dose per fraction; α/β is the constant for spinal cord late effect and equals 2. [Rades 2005, Nieder 2005, Sahgal 2012]
T16	Measurement 966 969	KPS
T17	Value 970 974	≥ 60
T18	Person 976 979	Age
T19	Value 980 994	≥ 18 years old
